All study participants were randomly assigned to an experimental treatment group that received subcutaneous injection of cagrilintide, once-weekly, in doses of either 0.3, 0.6, 1.2, 2.4, or 4.5 mg, as well as a one-daily 3.0 mg dose of liraglutide, and a volume matched placebo for control purposes
However, when liver cells from old patients were incubated in the blood from the younger group, the older cells started functioning in nearly the same way as the younger liver tissue
We believe that this letter, that has been linked to the original review, updates our readers sufficiently to the current situation
The absence of effects on IGF-1, glucose metabolism, and tissue growth reduces concerns about long-term hormonal consequences, but prudent medical oversight remains appropriate for any extended peptide use